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BBMT CONTINUES TO EXPAND;
WILL ADD MORE PAGES IN 2005
Monthly issues of Biology of Blood
and Marrow Transplantation will in-
crease in page count again next year.
The total number of editorial pages
this year, excluding supplements, has
increased from 768 to 864. Further
expansion to 960 pages next year has
been authorized by the ASBMT Exec-
utive Committee.
“The continued growth of the jour-
nal is a reflection of a steady increase in
the number of high-quality manuscripts
we are receiving,” said Robert Korn-
gold, PhD, editor-in-chief. “Growth in
revenues from advertising and reprints
will fund the journal expansion without
additional costs charged to member
dues.”
ABSTRACT DEADLINE IS OCT. 18
FOR TANDEM BMT MEETINGS
The combined 2005 annual meet-
ings of ASBMT and the Center for In-
ternational Blood and Marrow Trans-
plant Research (CIBMTR—formerly
IBMTR/ABMTR) will be held Feb. 10-14
at the Keystone Conference Center in
Keystone, Colo.
Abstracts are being accepted on
the ASBMT Web site at www.asbmt.
org. The deadline is Oct. 18.
The latest advances in the broad
field of cellular therapy and blood
and marrow transplantation will be
addressed in plenary sessions, con-
current sessions, workshops, poster
sessions and symposia. In addition,
about 60 original abstracts will be se-
lected for oral presentation.
The scientific program chair for
ASBMT is Stephen Emerson, MD,
PhD, University of Pennsylvania, and
the co-chairs for the CIBMTR are Ser-
gio Giralt, MD, M.D. Anderson Can-
cer Center, and Mark Litzow, MD,
Mayo Clinic.
Meeting registration and housing
information are on the Web site. The
deadline for advance registration at
reduced rates is Oct. 18. The housing
deadline at the Keystone Resort is Jan.
3, 2005, after which accommoda-
tions are on a space-available basis.
In addition to the five days of scien-
tific sessions for BMT clinicians and
investigators, there will be five related
conferences and courses:
● BMT Pharmacists (Feb. 9-10)
● Clinical Research Professionals
Data Management Workshops
(Feb. 9-11)
● BMT Center Administrators (Feb.
11-12)
● Transplant Nurses (Feb. 12-14)
● BMT Center Medical Directors
(Feb. 13)
NEW RESEARCH CENTER CREATED
BY NMDP AND IBMTR/ABMTR
The Medical College of Wisconsin’s
International Bone Marrow Trans-
plant Registry and Autologous Blood
and Marrow Transplant Registry (IB-
MTR/ABMTR) and the National Mar-
row Donor Program (NMDP) have
joined together to launched a new
research center.
The Center for International Blood
and Marrow Transplant Research
(CIBMTR) began operations on July 1,
bringing together the two organiza-
tions’ extensive expertise and re-
sources in the areas of blood and
marrow transplantation, biostatistics
and clinical cancer research. The new
center is expected to greatly expand
research activities during the next five
years to increase scientific knowledge
through:
● Prospective, multi-center trial de-
sign and implementation to ex-
plore new strategies to increase
the safety and success of trans-
plantation
● Retrospective studies of the
world’s largest blood and mar-
row transplant databases and
tissue sample repositories to iden-
tify the most promising transplant
approaches and the patients
most likely to benefit from BMT
therapy
● Research in immunobiology to
better understand how trans-
plantation works, including how
to harness the power of the im-
mune system to control cancer
● Transplant-focused biostatistics
expertise to assist researchers in
accessing, analyzing and present-
ing scientific studies
● Research to improve access to
health care services
“The CIBMTR will combine comple-
mentary capabilities of two leading
organizations in blood and marrow
transplantation to provide a single
point of focus for development and
support of transplant-related clinical
research,” said Jeffrey Chell, MD, chief
executive officer for the NMDP. “The
new center creates a structure that
better enables transplant researchers
to efficiently pursue multi-center clini-
cal trials and other important trans-
plant research—ultimately, to save
more patients’ lives.”
Mary Horowitz, MD, scientific direc-
tor of the IBMTR/ABMTR, said, “This
partnership will make it easier to de-
sign, conduct and support clinical
studies that involve large numbers of
patients from multiple transplant cen-
ters—the types of studies that are
needed to answer critical questions in
the field of blood and marrow trans-
plantation.”
“This is a collaboration that has
great potential for patients, donors
and health professionals,” said ASBMT
President Armand Keating, MD. “The
new alliance between the IBMTR/AB-
MTR and the NMDP creates a center
for transplant research that will help
accelerate the development of trans-
plant therapies, with corresponding
improvements in treatment out-
comes.”
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ASBMT, PAYERS MEET TO DISCUSS
BMT REIMBURSEMENT ISSUES
An ASBMT delegation met with rep-
resentatives of third-party payers in
July to discuss reimbursement of pa-
tient care costs in clinical trials, the
Society’s evidence-based reviews, the
BMT Clinical Trials Network, the stan-
dardized Request for Information
(RFI), and transplant center effects on
outcomes of care.
The meeting in Chicago was orga-
nized by the United Network for Or-
gan Sharing (UNOS) and included
representatives from 11 companies:
Aetna, Blue Shield of Florida, Blue
Quality Centers for Transplant, Cigna
LifeSource, First Health, Interlink, Kai-
ser Permanente, LifeTrac, MultiPlan,
PacificCare and Wellpoint.
GUIDELINE CLEARINGHOUSE
ACCEPTS ASBMT NHL REVIEW
The ASBMT evidence-based review
for large cell B-cell non-Hodgkin’s lym-
phoma has been accepted for listing
with the National Guideline Clearing-
house (NGC).
The NGC is a resource for evidence-
based clinical practice guidelines for
physicians and other health profes-
sionals, health plan managers and
purchasers and integrated delivery
systems. It provides ready online ac-
cess to objective, detailed information
on clinical practice guidelines.
The evidence-based review con-
cluded that stem cell transplantation in
the treatment of large cell B-cell non-
Hodgkin’s lymphoma is more effective
than conventional chemotherapy for:
● first chemotherapy-sensitive relapse
● first complete remission in high/
intermediate-high risk IPI patients
● as high-dose sequential therapy
in intermediate-high/high risk
untreated patients
The review was published in Biol-
ogy of Blood and Marrow Transplan-
tation, Vol. 7, No. 6.
The NGC is jointly sponsored by
the Agency for Healthcare Research
and Quality (AHRQ) and the U.S. De-
partment of Health and Human Ser-
vices (HHS), in partnership with the
American Medical Association (AMA)
and the American Association of
Health Plans-Health Insurance Associ-
ation of America (AAHP-HIAA).
To be accepted, a clinical practice
guideline must meet criteria including:
● It contains systematically devel-
oped statements including recom-
mendations, strategies or informa-
tion that assists physicians and
other health care practitioners and
patients to make decisions about
appropriate health care for specific
clinical circumstances.
● It was produced under the aus-
pices of medical specialty associa-
tions; relevant professional societ-
ies; public or private
organizations; government agen-
cies at the federal, state or local
level; or health care organiza-
tions or plans.
● Corroborating documentation
can be produced, verifying that a
systematic literature search and
review of existing scientific evi-
dence published in peer-re-
viewed journals was performed
during the guideline develop-
ment process
This is the second ASBMT evidence-
based review to be accepted for list-
ing with the National Guideline Clear-
inghouse.
EVIDENCE-BASED REVIEWS
SLIDE SHOW IS AVAILABLE
A PowerPoint presentation on evi-
dence-based reviews of stem cell
transplantation for (1) multiple my-
eloma and (2) non-Hodgkin’s lym-
phoma has been posted on the
ASBMT Web site, where it can be
viewed online or downloaded for
presentations to managed care medi-
cal directors, case managers and other
health care plan decision makers. The
URL is www.asbmt.org/policystat/
policy.html.
MESENCHYMAL CELL CONFERENCE
Mesenchymal stem cell biology,
stem cell plasticity and cell therapy for
cardiac, pulmonary and neurologic
diseases will be addressed at the 4th
annual Mesenchymal and Nonhema-
topoietic Stem Cells Conference, Oct.
14-15, in New Orleans. ASBMT is a
co-sponsor. Information and registra-
tion are available online at www.
neworleansmscmeeting.org.
DONOR SAFETY CONFERENCE
Safety, risks, ethics and clinical stan-
dards for adult and pediatric alloge-
neic donors of stem cells will be ad-
dressed in a conference Sept. 21-22
in Arlington, Va. The conference is
sponsored by the NHLBI, with sup-
port from ASBMT. Information and
registration are available online at
http://www.donorsafety.org.
CONTRACTING, REIMBURSEMENT
COST CONTAINMENT CONFERENCE
The 6th annual Conference on
Transplant Contracting, Cost Contain-
ment and Reimbursement is scheduled
for Sept. 20-21 in Chicago, co-spon-
sored by ASBMT and produced by the
Center for Business Intelligence. An
agenda and registration information—
including a discount of $400 for ASBMT
members – are online at www.cbinet.
com/events/FB454/index.html
ONLINE PRESENTATION ADDRESSES
BMT VOLUNTARY ACCREDITATION
“Voluntary Accreditation in Cell
Therapy: Working Toward Global
Standards” is the title of a presenta-
tion given at the International Society
for Cellular Therapy (ISCT) at its recent
annual meeting in Dublin, Ireland.
The presentation offers an up-to-the-
moment look at accreditation of he-
matopoietic stem cell transplant facil-
ities, including cord blood banks,
across North America and around the
world. The PowerPoint presentation
can be downloaded or viewed on-
line at unmc.edu/Community/fahct/
Voluntary%20Accreditation_Dublin.
ppt.
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